SCHEMBL800351

SCHEMBL800351

Nc1ncnc2c1ncn2[C@@H]1O[C@H]([C@H](O)C(F)(F)F)[C@@H](O)[C@H]1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.64
▸ WDR77 Q9BQA1 1/20 0.64
▸ AHCY P23526 11/20 0.61
▸ ADORA2A P29274 2/20 0.60
▸ ADORA2B P29275 2/20 0.60
▸ ADORA3 P0DMS8 2/20 0.60
▸ DPP4 P27487 1/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ SLC28A1 O00337 1/20 0.60
▸ MAP3K7 O43318 1/20 0.60
▸ SLC28A2 O43868 1/20 0.60
▸ GAPDH P04406 1/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ ADORA1 P30542 1/20 0.60
▸ STAT6 P42226 1/20 0.60
▸ PI4KA P42356 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ PI4K2B Q8TCG2 1/20 0.60
▸ DOT1L Q8TEK3 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL800776 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL28017954 0.90 EGFR (0.62) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL31680251 0.88 AHCY (0.68) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL397800 0.88 AHCY (0.68) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL10997934 0.87 AHCY (0.65) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL2120934 0.87 PRMT5 (0.67) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL6671788 0.87 AHCY (0.67) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL7803295 0.87 AHCY (0.67) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL25390909 0.86 AHCY (0.66) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL2040666 0.86 PRMT5 (0.66) PRMT5WDR77AHCYADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070411-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 — — US disclosed
US-20120070411-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070411-A1 SUBSTITUTED NUCLEOTIDE ANALOGS PNP, NTPCR, NUDT1 PRMT5 3112/4885WDR77 1331/4885AHCY 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback